Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Q3 2023 Oncopeptides AB Earnings Call Transcript

Nov 08, 2023 / 08:00AM GMT
Release Date Price: kr5 (-5.97%)
Sofia Heigis
Oncopeptides AB - CEO

Hi, everyone, and welcome to the Oncopeptides' presentation for investors and media of our report for the third quarter. These are the standard disclaimers.

My name is Sofia Heigis, CEO of Oncopeptides. And with me on the call, I have our CFO, Holger Lembrér. After my introduction, Holger will give you the financial summary for the second quarter, followed by commercial and strategy update by myself.

Looking at the third quarter, sales for Pepaxti in Europe continue to show a positive trend with SEK2.6 million in revenue in Q3, while volumes remain at relatively low levels the important upward trend continues. The number of sold vials in Germany has tripled in Q3 versus Q2.

While this presentation will focus on Q3, I'm happy to also share that the positive trend continues into the fourth quarter as the number of sold vials in Europe in October alone almost reached the number of the entire third quarter.

We used the numbers of sold vials as a key metric, given it illustrates and allows for comparability across markets and time

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot